NLS

Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against

Onxeo has turned to the public markets for cash to fuel its research and development ambitions, starting a rights issue in a bid to raise up to €41.6 million ($52.2 million). The Franco-Danish biotech plans to use the cash to expand a Phase III study of its liver cancer drug and prepare to advance its […]

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, a once-daily human glucagon-like peptide-1 (GLP-1) analogue, to […]

Norwegian company Bionor Pharma is in talks with the U.S. Federal Drug Administration (FDA) about a possible collaboration on a study to test a trial HIV vaccine early next year.  Bionor reported strong results in one of its tests of vaccine Vacc-4x in combination with the drug Revlimid. Vacc-4x works by activating the body’s immune system to kill […]

Moberg Pharma AB has appointed Jeff Vernimb as General Manager for its U.S. operations and a member of Moberg’s management team, effective December 15. Vernimb brings to Moberg more than 25 years of experience in consumer health products’ marketing and sales in multi-national and smaller entrepreneurial businesses.  Prior to his position with Moberg, Vernimb was vice […]

Camurus and Braeburn Pharmaceuticals announced that they have entered into an exclusive license agreement for the long-Camurus buprenorfinprodukt, CAM2038, for the treatment of opiate dependence and pain. Braeburn receive exclusive licensing rights in North America and an option for Japan, Korea, Taiwan and China. Camurus retains all rights in the rest of the world.  Under […]